Fully Replicate Study [Study As­sess­ment]

posted by NK – India, 2021-04-26 09:46 (432 d 07:09 ago) – Posting: # 22323
Views: 1,868

Dear All,

We did BE study (both fasting and fed) for ER formulation of a drug (HVD), with fully replicated design (RTRT/TRTR) for USFDA. The protocol says, plasma samples from subjects who complete all the four periods will be analyzed and will be included for PK and statistical analysis.

Where we observed following:Can we include Subject A & B for statistical analysis (protocol not specified about handling subject with three periods data. (ie. one T & two R and one R & Two T).

To handle this kind of situation in future, Can we mention in the protocol to exclude the subject (outlier) with above scenario.

Thanks in advance

Regards
NK


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,181 posts in 4,647 threads, 1,572 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Saturday 16:55 CEST (Europe/Vienna)

Reach for the stars,
even if you have to stand on a cactus.    Susan Longacre

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5